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ABSTRACT
Objective To determine whether the previously observed
25% reduction in breast cancer mortality in Copenhagen
following the introduction of mammography screening
was indeed due to screening, by using an additional
screening region and five years additional follow-up.
DesignWeusedPoissonregressionanalysesadjustedfor
changes in age distribution to compare the annual
percentage change in breast cancer mortality in areas
wherescreeningwasusedwiththechangeinareaswhere
it was not used during 10 years before screening was
introduced and for 10 years after screening was in
practice (starting five years after introduction of
screening).
Setting Copenhagen, where mammography screening
started in 1991, and Funen county, where screening was
introduced in 1993. The rest of Denmark (about 80% of
the population) served as an unscreened control group.
Participants All Danish women recorded in the Cause of
Death Register and Statistics Denmark for 1971-2006.
Main outcome measure Annual percentage change in
breast cancer mortality in regions offering mammography
screening and those not offering screening.
ResultsInwomenwhocouldbenefitfromscreening(ages
55-74 years), we found a mortality decline of 1% per year
in the screening areas (relative risk (RR) 0.99, 95%
confidence interval (CI) 0.96 to 1.01) during the 10 year
period when screening could have had an effect (1997-
2006). In women of the same age in the non-screening
areas, there was a decline of 2% in mortality per year
(RR0.98,95%CI0.97to0.99)inthesame10yearperiod.
In women who were too young to benefit from screening
(ages 35-55 years), breast cancer mortality during 1997-
2006 declined 5% per year (RR 0.95, CI 0.92 to 0.98) in
the screened areas and 6% per year (RR 0.94, CI 0.92 to
0.95) in the non-screened areas. For the older age groups
(75-84 years), there was little change in breast cancer
mortality over time in both screened and non-screened
areas. Trends were less clear during the 10 year period
beforescreeningwasintroduced,withapossibleincrease
in mortality in women aged less than 75 years in the non-
screened regions.
Conclusions We were unable to find an effect of the
Danish screening programme on breast cancer mortality.
The reductions in breast cancer mortality we observed
in screening regions were similar or less than those in
non-screened areas and in age groups too young to
benefit from screening, and are more likely explained by
changes in risk factors and improved treatment than by
screening mammography.
INTRODUCTION
Comprehensivesystematicreviewsofrandomisedtrials
of mammography screening have estimated that mam-
mographyreducesbreastcancermortalityby15-16%.
12
Thetrialsinthesereviewswerecarriedoutdecadesago,
however,andpubliclyavailablescreeningprogrammes
could yield a different effect from that in the trials
because of differences in the qualifications of the staff,
type of equipment, and uptake rates. Furthermore,
there have been advances in treatment since the trials
were completed and “breast awareness” has increased.
It is therefore important to evaluate continuously the
effect of public mammography screening programmes
to ensure that they live up to expectations.
Denmarkisuniquelysuitedforobservationalstudies
of mammography screening because the country has
had a period of 17 years where only about 20% of the
populationhasbeenofferedscreening;thatis,thereisa
concomitant non-screened control group. There are,
however, substantial problems in using observational
studies to estimate the effect of screening.
3 For exam-
ple, a decline in breast cancer mortality following the
introduction of screening would not necessarily be
caused by screening.
A cohort study from 2005 by Olsen et al compared
Copenhagen,wherescreeningwasintroducedin1991,
with non-screened areas in Denmark and reported a
25% reduction in breast cancer mortality that was
attributed to screening.
4 However, there are three
important concerns about this result.
5-7 Firstly, the full
mortality reduction appeared three years after screen-
ingstartedanddidnotincreaseintheremainingobser-
vation period.
4 The mechanism of screening is to
advance the time of diagnosis; therefore, an effect is
not expected to appear in the first few years after its
introduction but is expected to emerge after about
five years and increase with further follow-up.
3 That
the full effect appeared after only three years suggests
that factors other than screening are the cause of the
mortality reduction observed.
1The Nordic Cochrane Centre,
Rigshospitalet, University of
Copenhagen, Denmark
2Norwegian Institute of Public
Health, Oslo, Norway
Correspondence to: K J Jørgensen
kj@cochrane.dk
Cite this as: BMJ 2010;340:c1241
doi:10.1136/bmj.c1241
BMJ | ONLINE FIRST | bmj.com page 1 of 6Secondly, the study included only Copenhagen,
although the county of Funen introduced screening in
1993,hasapopulationofasimilarsize,andhasahigher
proportion of women who repeatedly attend screening
rounds(76%v53%).
8Oneoftheauthorsofthepaperby
Olsen et al heads the Funen screening programme and
should have had access to detailed data.
Thirdly, the study did not describe breast cancer
mortality rates in women who were too young or too
old to have benefited from screening. An absence of
similar reductions in breast cancer mortality among
these women would have strengthened the study’s
conclusions.
We hypothesised that if the reduction in breast can-
cer mortality that Olsen et al observed in Copenhagen
was due to screening, a similar reduction should have
occurredinFunenbutnotinthenon-screenedareasor
in age groups outside those that could potentially have
benefited.
METHODS
We retrieved data on female breast cancer mortality
during 1971-2006 from the Cause of Death Register
through the National Board of Health. Compared
with Olsen et al,
4 we had access to data from five addi-
tionalyears.Thenumbersofbreastcancerdeathswere
listed for each year, administrative region, and five
year age group. The corresponding female population
statistics were obtained from Statistics Denmark.
9
Organised mammography screening of women
aged 50-69 years began on 1 April 1991 in Copenha-
gen municipality, 1 November 1993 in Funen county,
and 1 June 1994 in Frederiksberg municipality.
10 The
Frederiksberg programme, which comprised only
about 10000 women, was incorporated into the
Copenhagen programme on 1 January 1997.
10 The
Copenhagen and Funen programmes both include
about 50000 women.
We divided the data into two regions. Copenhagen
(including Frederiksberg municipality) and Funen
county were considered together as “screening areas”
to reduce the effect of random fluctuations. These
screeningareaswere compared withthe “non-screened
areas,” comprising the rest of Denmark (about 80% of
the population).
The mortality data for both screening and
non-screening areas were divided into three age
bands. The 55-74 years band was composed of the
women most likely to have benefited from a pro-
gramme targeted at women aged 50-69 years, such as
that in Denmark. Most women who die aged
50-55 years would have had their breast cancers
detected before they were invited to screening. On
the other hand, the majority of women aged
70-74 years when they died would have been diag-
nosed and offered screening when they were younger,
and by six years after organised screening began, all
women aged 70-74 years would have been previously
offered screening.
In contrast, breast cancer mortality in women aged
35-54 years and 75-84 years would largely be unaf-
fected by screening, although by the end of the obser-
vation period some women aged 75-84 years could
havebenefitedthroughdetectionofslow growingcan-
cers. These age groups also serve as control groups.
We first defined the period when screening could
have had an effect. In randomised trials of mammogra-
phy screening, an effect began to emerge about five
years after screening was introduced,
3 which is 1996 in
Copenhagen and 1998 in Funen. We used 1997 as a
compromise start date in our combined analysis of the
tworegions.Thisprovideda10yearobservationperiod
(1997-2006) when screening could have had an effect.
Forcomparison,weuseda10yearperiodthatended
when screening was introduced (1982-1991), but we
provide mortality graphs back to 1971 for complete-
ness. The last year before organised screening was
introduced was 1990 in Copenhagen and 1992 in
Funen, so we used 1991 as a compromise.
We used Poisson regression analyses to quantify
changes in mortality trends, comparing regions and
agegroupswithandwithoutorganisedmammography
Table 1 |Woman years of observation, number of breast cancer deaths, and average rates per 100 000 women in screened
and non-screened areas
Screened areas Non-screened areas
1982-91 1992-96 1997-2006 1982-91 1992-96 1997-2006
Number of woman years
35-54 years 1 174 997 640 700 1 338 266 5 509 889 3 005 488 6 233 027
55-74 years 1 218 157 492 081 957 797 3 925 135 2 002 687 4 471 369
75-84 years 478 800 223 441 370 101 1 142 623 625 693 1 312 095
Number of breast cancer deaths
35-54 years 457 257 390 1961 1055 1657
55-74 years 1478 658 980 4281 2326 4739
75-84 years 937 429 722 2003 1152 2352
Average number of breast cancer deaths per 100 000 women
35-54 years 39 40 29 36 35 27
55-74 years 121 134 102 109 116 106
75-84 years 196 192 195 175 184 179
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tion.StatisticalanalysesweremadeusingEgretversion
2.0.3 (Cytel, Inc, Cambridge, MA) and graphs were
made in Microsoft Excel 2000.
RESULTS
Thenumberofwomanyearsandthenumberofdeaths
attributed to breast cancer in the 36 year observation
period in the screened areas and in the non-screened
areas are presented in table 1.
Breast cancer mortality among women who could benefit
from screening (ages 55-74 years)
In the 10 year period when screening could have had
an effect, breast cancer mortality among women who
could benefit from screening (ages 55-74 years)
declined by 1% a year in the screened areas (relative
risk (RR) 0.99; 95% confidence interval (CI) 0.96 to
1.01) and by 2% in the non-screened areas (RR 0.98,
95% CI 0.97 to 0.99; fig 1; table 2). Before screening
wasintroduced,breastcancermortalityratesincreased
by 1% a year in the screened areas (RR 1.01, 95% CI
0.99 to 1.03) and by 2% a year in the non-screened
areas (RR 1.02, 95% CI 1.01 to 1.03).
Breast cancer mortality among women too young to
benefit from screening (ages 35-54 years)
In the most recent 10 year period, breast cancer mor-
talityamongwomentoo youngtobenefitfromscreen-
ing (ages 35-54 years) declined by 5% a year in the
screened areas (RR 0.95, 95% CI 0.92 to 0.98) and by
6%inthenon-screenedareas(RR0.94,95%CI0.92to
0.95; fig 1). Before screening was introduced, breast
cancer mortality rates increased by 2% a year in the
screened areas (RR 1.02, 95% CI 0.99 to 1.06) and
were stable in the non-screened areas (RR 1.00, 95%
CI 0.99 to 1.02; table 2).
Breast cancer mortality among women too old to benefit
from screening (ages 75-84 years)
There were no significant changes in the breast cancer
mortalitytrendsamongwomentoooldtobenefitfrom
screening(ages75-84years),bothinthescreenedareas
and in the non-screened areas (fig 1; table 2).
DISCUSSION
Our findings contradict the conclusions of a recent
observational study that reported a 25% reduction in
breast cancer mortality in screening areas of Denmark
(Copenhagen) compared with non-screened areas and
attributed this drop to the effect of screening.
4 Our
study included three screening areas in Denmark,
non-screened age groups, and an additional five years
offollow-up,yetwewerenotabletofindaneffectofthe
Danishscreeningprogrammeonbreastcancermortal-
ity. We also note that in the age group too young to
have benefited from screening, women experienced
proportionately larger reductions in breast cancer
mortality after screening was introduced than did
those that could have benefited from screening.
The reduction in breast cancer mortality in Copen-
hagen started too early after screening was introduced
forscreeningtobeaplausiblecause,althoughadecline
within the first three years of screening formed the
basis for the conclusion in the previous study,
4 and
the reduction in breast cancer mortality in the second
screened region, Funen, began before organised
screening (see web extra). This suggests that causes
other than screening were responsible for the changes
in breast cancer mortality—for example, changes in
risk factors and improvements in treatment may have
occurred sooner in some areas than in others.
Strengths and weaknesses of our study
Opportunistic screening is rare in Denmark so could
notbethereasonforthereductioninbreastcancermor-
tality in the non-screened areas. Only 2% of women
aged 20-99 years and 3% of women aged 50-69 years
had a mammogram outside organised screening in
2000, and some of the mammograms were diagnostic
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Fig 1 | Unadjusted breast cancer mortality rates for screened
and non-screened areas in Denmark
Table 2 |Annual change in the relative risk of breast cancer
death (with 95% confidence intervals) 10 years before
screening was introduced and 10 years during which
screening could have had an effect on breast cancer
mortality
Before screening
(1982-91)
After screening
(1997-2006)
Ages 35-54 years
Screened areas 1.02 (0.99 to 1.06) 0.95 (0.92 to 0.98)
Non-screened areas 1.00 (0.99 to 1.02) 0.94 (0.92 to 0.95)
Ages 55-74 years
Screened areas 1.01 (0.99 to 1.03) 0.99 (0.96 to 1.01)
Non-screened areas 1.02 (1.01 to 1.03) 0.98 (0.97 to 0.99)
Ages 75-84 years
Screened areas 0.99 (0.97 to 1.02) 1.00 (0.98 to 1.03)
Non-screened areas 0.99 (0.98 to 1.02) 0.99 (0.98 to 1.02)
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11 Carcinoma in
situ, which is detected almost entirely through screen-
ing, had a fairly constant incidence rate throughout the
observation period in the non-screened areas, but the
rates doubled in the screened regions when screening
was introduced and have remained at that level.
12
In the study by Olsen et al, deaths from breast can-
cersdiagnosedbefore1991,whenscreeningwasintro-
duced in Copenhagen, were excluded from the
analysis.
4 It may be reasonable to exclude breast can-
cersdetectedbeforescreeningwasintroducedbecause
screening cannot affect their prognosis. Excluding
such cancers is unlikely to have had an effect on our
results, however, because the effect diminishes with
time.Therefore,adifferenceinbreastcancermortality
of 25% between screened and non-screened areas, if
true, would be expected to be clearly apparent after
14-16 years with organised screening.
Furthermore, in 1986, before screening was intro-
duced in the United Kingdom, the Forrest report on
screening for breast cancer noted that population sta-
tistics could be used to see the mortality benefit from
screeningthatwasexpectedonthebasisofresultsfrom
randomisedtrials.
13Wedidnotseethisexpectedeffect
in Denmark.
Wecomparedopencohortsbecauseourdatadidnot
allow identification of individual women. We could
not therefore take account of migration between
screened and non-screened regions. However, mobi-
lity in the screened age groups is limited in Denmark.
We also note that our open cohort design cannot be
used to explain why breast cancer mortality declined
in the non-screened areas at a similar rate as in the
screened areas, and that the decline was larger in
women who were too young to have benefited from
screening. We consider it unlikely that there were
regionaldifferencesintheuseofhormonereplacement
therapy that could explain our findings because Den-
mark is a homogeneous country and the screened and
the non-screened areas had a similar proportion of
cities and rural areas.
Comparison with previous studies
Olsen et al reported the results of a complicated statis-
tical model, and the choice of model can have a sub-
stantialimpactontheresults.Someofthesameauthors
havemorerecentlyreportedresultsfromseveralmod-
els, one of which showed an increase in breast cancer
mortality in Copenhagen among screened women
relative to women in the non-screened areas.
14 The
authors asserted that the model they published origin-
ally, which gave the most favourable result for screen-
ing, should be preferred, but did not explain why.
None of the models was validated, and it is not clear
whether the preferred model was selected after other
models had been tried first. Our study does not use a
complicated statistical model; instead we present the
raw data and simple analyses.
Olsen et al assumed that women in the screened
areas and those in the non-screened areas received
identical care because national guidelines for breast
cancer treatment have been in use in Denmark since
1977.
4 Guidelines, however, may not be used to the
letterinclinicalpractice.InJanuary2007,forexample,
several women in one of the non-screened regions
were compensated financially for having received
treatment that did not live up to “best specialist
standards.”
1516 If the standard of care were lower in
the non-screened areas, it would only strengthen our
findings that screening cannot be responsible for the
declines in breast cancer mortality we observed.
All breast cancer treatment in Copenhagen takes
place at university hospitals that provide specialised
care and have a high volume of patients, whereas
careismorevariableinFunen,andtherehasbeencon-
siderablepressuretocentralisebreastcancertreatment
inotherregions.
15Thereductionin breastcancermor-
talityinCopenhagenstartedearlierthanexpectedafter
screening was introduced and the reduction in breast
cancer mortality in Funen began before organised
screeningstarted(see webextra);thereforethemortal-
ity difference between Copenhagen and non-screened
regionsfoundinthepreviousstudymightpartlyreflect
betterorganisationoftreatmentandearlierimplemen-
tationofimprovementsintherapy(forexample,useof
tamoxifen).
Olsen et al calculated that the reduction in breast
cancer mortality among those who actually attended
screening was 37%.
4 However, there was no relevant
control group to compare those who actually attended
screening with, because it is impossible to know which
womeninthenon-screenedareaswouldhaveattended
screening had it been offered. Such results are invalid
because of the “healthy screenee effect.” People who
attend screening are more healthy in general than
those who choose not to participate, and have been
described as “healthy, well educated, affluent, physi-
cally fit, fruit and vegetable eating, non-smokers with
long lived parents.”
17
It is common for mortality estimates to be adjusted
for attendance to mammography screening, but this
measure is equivalent to preferring a per protocol ana-
lysisoveranintentiontotreatanalysis.Bycomparison,
one does not adjust for compliance in drug trials
becausesuchadjustmentsarebiasprone.Forexample,
in a trial that failed to find an effect of clofibrate on
cardiac mortality, the authors reported a large effect
among those who took at least 80% of the drug
(P=0.0001) but found a similar “effect” among com-
pliers in the placebo group (P=5×10
−16).
18
The handbook on breast cancer screening from the
International Agency for Research on Cancer advises
that observational studies should not be regarded as
providing evidence of an effect of screening.
3 We
agree that positive evidence for an effect should come
fromrandomisedtrials.Theeffect ofscreeningis equi-
vocal and has been estimated to be only about 15-16%
in the two most comprehensive systematic reviews of
randomised trials.
12Small effect sizes render observa-
tional studies particularly problematic, but observa-
tional studies are useful for monitoring the effect in
clinical practice.
12 Contrary to expectations, a study
RESEARCH
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itywereofasimilarmagnitudeincountriesnotoffering
screeningasinthoseofferingscreening,withthegreat-
est declines among women who were too young to be
offered screening, which is similar to our findings.
19
Many studies have used population statistics to esti-
mate the effect of mammography screening
programmes.
20-23 Like the study by Olsen et al, most
of them include only women in the age group that
could benefit from screening and do not compare
trends in breast cancer mortality with those in an
unscreened group, thus disregarding the effects of
otherimportantfactorsthatcouldchangeinthescreen-
ing period (such as treatment).
These studies also often claim to have compensated
for lead time and length bias, with highly variable
assumptions of their size. This is not surprising, as no
oneknows exactly howlarge leadtime and length bias
for breast cancer screening are. Such shortcomings
question the conclusions in these studies.
Comparison with other countries
Results from other countries
19 support our findings. In
the UK, where screening started in 1988, the decline in
breastcancermortalityfrom1989until2007was41%in
women aged 40-49 years, who were not invited to
screening, 41% in women aged 50-64 years, who were
invitedtoscreeningfrom1988,and38%inwomenaged
65-69 years, who were invited from 2002 (fig 2).
24
Furthermore, the drop in breast cancer mortality in
the relevant age group began before the screening pro-
gramme started, and was largest in the age group that
was too young to be invited (40-49 years) if the whole
observation period is considered (1971-2007).
25
In the United States, a particularly pronounced
trend shift in breast cancer mortality has been
observed, with a substantial decline since the middle
of the 1980s.
27 However, the starting point for the
decline is probably a random high, and there have
been large changes in the use of surgery and che-
motherapy that might affect the drop.
28 Groups of epi-
demiologists analysing these data independently
arrived at a median estimate of the effect of screening
of only 15%.
27
In countries with a less pronounced trend shift fol-
lowing the introduction of mammography screening,
ornoshiftatall,
19suchanalyseswouldlikelyfailtofind
an overall positive effect of screening on breast cancer
mortality. We note, for example, that in Sweden,
where screening started in 1986 and where uptake
rates are very high, the mortality curves for the rele-
vant age groups (45-55 years and 55-74 years) show a
constant decline through the decades (fig 3). This
decline started before screening was introduced,
which does not suggest a screening effect.
Furthermore, the decline in the youngest age group
(45-54 years, some of whom are offered screening in
some areas in Sweden) is similar to that in the age
group that would be expected to benefit the most
from screening (55-74 years, who stand to benefit
fromscreeninginallcounties).Somewhatsurprisingly,
there was a pronounced decline in breast cancer mor-
talityintheoldestagegroup(75-84years)thatstopped
whenscreeningwasintroduced(fig3).Thisiscontrary
towhatwouldbeexpectedandisunlikelytohaveany-
thing to do with screening.
Conclusions
WewereunabletofindaneffectoftheDanishscreening
programme on breast cancer mortality. The reductions
in breast cancer mortality we observed in screened
regions were similar or larger in non-screened regions
andinagegroupsyoungerthanthatscreened.Themor-
tality reduction is therefore more likely to be explained
by changes in risk factors and by improved treatment
thanbyscreeningmammography.Ourresultsaresimi-
lar to what has been observed in other countries with
nationally organised programmes. We believe it is
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promised effect on breast cancer mortality.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
A Danish study has estimated that breast cancer mortality in Copenhagen has fallen by 25%
since 1991 following the introduction of screening mammography
However, the full mortality reduction appeared three years after screening started (that is,
several years earlier than expected), the study did not describe breast cancer mortality rates
in women who were too young or too old to have benefited from screening, and only one of
two available screening regions was included
If the reduction in breast cancer mortality in Copenhagen was due to screening, a similar
reductionshould beseeninthe other region ofDenmark thatusedscreening, but not innon-
screened areas or in age groups other than those that could potentially have benefited
WHAT THIS STUDY ADDS
Among women who could benefit from screening (ages 55-74 years), there was a similar or
larger decline in breast cancer mortality among women in areas that did not use screening
than in those that did
The reductions in breast cancer mortality among women too young to benefit from screening
(ages 35-54 years) were much larger than those among women in the screened age groups
The reductions in breast cancer mortality we observed are more likely explained by changes
in risk factors and by improved treatment than by screening mammography
RESEARCH
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